{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-001714","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.779020+00:00","generated_at":"2026-06-15T16:55:24.900765+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entera Bio Q1 net loss $2.2M vs $3.8M YoY; cash $10.7M into Q3 2024","bullets":["Net loss of $2.2M, $0.08 per share, compared to $3.8M, $0.13 per share in Q1 2022.","Cash and equivalents $10.7M as of Mar 31, 2023; expects cash to fund ops into Q3 2024.","R&D expenses $0.9M (down 47% YoY); G&A expenses $1.3M (down 41% YoY).","Plans to initiate PK study of oral PTH(1-34) for hypoparathyroidism H1 2023, topline H2 2023.","Amgen research collaboration discontinued by mutual agreement after 4+ years."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-001714","json":"https://secwatch.observer/filing/0001178913-23-001714.json","markdown":"https://secwatch.observer/filing/0001178913-23-001714.md","text":"https://secwatch.observer/filing/0001178913-23-001714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/0001178913-23-001714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:55:24.900765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cf6b4110d6ac145592082f411dc17c35e3ad04b","claim":"Entera Bio Ltd. reported first quarter ended March 31, 2023 results: net income Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023, EPS $0.08 per ordinary share (basic and diluted).","evidence_excerpt":"Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/0001178913-23-001714-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023"},{"label":"EPS","value":"$0.08 per ordinary share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}